Droia Oncology Ventures

https://www.droiaventures.com

Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease. Droia manages over EUR 450 million (USD 550 million) which it invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patient lives. *

	Start	2017-01-19 existent
	Industry	venture capital
	Industry 2	cancer drug

	City	n. a.
	Tel	+32-2-880-6730
		Address record changed: 2021-05-22

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	250,000,000 (capital under management (2018) 2018-09-28)

		* Document for »About Section«: Droia Ventures. (5/11/21). "Press Release: Droia Ventures Raises a New Fund of EUR 220 Million to Target Genetic Diseases and Expands Leadership Team with George Golumbeski". Brussels.

		Record changed: 2024-02-12

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)